Is MUC1 a viable therapeutic target for patients with the asbestos-induced tumour malignant mesothelioma?

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/634377

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of people each year. Most patients are diagnosed with advanced disease. We are investigating the use of a specific marker, called MUC1, to improve mesothelioma diagnosis. Improved diagnosis will reduce the time taken to commence treatment. It will also reduce hospital costs and the number of surgical procedures a patients must undergo.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $465,068.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Respiratory Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

MUC1 | PGP6 | abestos related disease | asbestos disease | diagnosis | epithelial membrane antigen (EMA) | mesothelioma | thoracic disease

Related Links